{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-23-000011","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.994640+00:00","generated_at":"2026-06-19T06:27:31.705656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Halozyme Q4 revenue up 78% to $181M; 2023 guidance $815-845M","bullets":["Q4 revenue $181M (+78% YoY); full-year revenue $660.1M (+49% YoY).","Q4 GAAP diluted EPS $0.42; non-GAAP diluted EPS $0.48. Full-year GAAP EPS $1.44; non-GAAP EPS $2.21.","Record Q4 royalty revenue $106M (+69% YoY); full-year royalties $360.5M (+77% YoY).","2023 guidance: revenue $815-845M (23-28% growth), EBITDA $415-440M (>30% growth), non-GAAP EPS $2.50-2.65.","Completed $110M ASR; $350M of $750M buyback executed; elected Barbara Duncan to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-23-000011","json":"https://secwatch.observer/filing/0001159036-23-000011.json","markdown":"https://secwatch.observer/filing/0001159036-23-000011.md","text":"https://secwatch.observer/filing/0001159036-23-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/halo-20230221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:27:31.705656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"278df542fa5c8a7befe54137e71caf5e18b7b476","claim":"HALOZYME THERAPEUTICS, INC. reported the full year ended December 31, 2022 results: revenue $660.1 million, EPS $1.44 per diluted share.","evidence_excerpt":"Full Year 2022 Revenue Increased 49% YOY to $660.1 million; GAAP Diluted Earnings per Share of $1.44 and Non-GAAP Diluted Earnings per Share of $2.21","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$660.1 million"},{"label":"EPS","value":"$1.44 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"62251297e1265d590af011ad8f0b8370cfc74b4c","claim":"HALOZYME THERAPEUTICS, INC. reported 2023 results: revenue $815 million to $845 million. Guidance initiated.","evidence_excerpt":"2023 Revenue Guidance of $815 million to $845 million, Representing 23%-28% YOY Growth; EBITDA of $415 million to $440 million, Representing >30% YOY Growth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"$815 million to $845 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e10f0527f9e778fe3c9ce8837b5f55b6f055aabf","claim":"HALOZYME THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $181 million, EPS $0.42 per diluted share.","evidence_excerpt":"Fourth Quarter Revenue Increased 78% YOY to $181 million; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.48","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$181 million"},{"label":"EPS","value":"$0.42 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}